Bruce Rogers, PhD is President of Morphic Therapeutic, where he started as Chief Scientific Officer in 2016. He brings over 25 years of drug discovery and development experience across pre-clinical and clinical development programs, medicinal chemistry, structural biology, translation, biology, DMPK, partnering and R&D strategy. Prior to Morphic he was most recently the Head of Neuro-Opportunities at Pfizer, where he led a team focused on entrepreneurial approaches to long standing CNS biology challenges, including direct brain delivery of protein therapeutics for PD and oncology approaches. Prior to that Bruce spent 16 years in positions of increasing responsibility within the medicinal chemistry organization at Pfizer and Pharmacia, and during his time there led multiple discovery and early clinical development teams, with his group advancing over a dozen small molecule candidates into clinical trials for a broad range of neuroscience indications. Bruce has co-authored more than 60 scientific publications, reviews and abstracts and is a co-inventor on over 85 patents and patent applications. He holds a BA in chemistry from the University of Minnesota and a PhD in organic chemistry from the University of California at Irvine. He was a National Institutes of Health postdoctoral fellow at the University of California prior to joining the pharmaceutical industry.